Correlation of Intravascular Ultrasound Findings With Histopathological Analysis of Thrombus Aspirates in Patients With Very Late Drug-Eluting Stent Thrombosis

Background— Intravascular ultrasound of drug-eluting stent (DES) thrombosis (ST) reveals a high incidence of incomplete stent apposition (ISA) and vessel remodeling. Autopsy specimens of DES ST show delayed healing and hypersensitivity reactions. The present study sought to correlate histopathology of thrombus aspirates with intravascular ultrasound findings in patients with very late DES ST. Methods and Results— The study population consisted of 54 patients (28 patients with very late DES ST and 26 controls). Of 28 patients with very late DES ST, 10 patients (1020±283 days after implantation) with 11 ST segments (5 sirolimus-eluting stents, 5 paclitaxel-eluting stents, 1 zotarolimus-eluting stent) underwent both thrombus aspiration and intravascular ultrasound investigation. ISA was present in 73% of cases with an ISA cross-sectional area of 6.2±2.4 mm2 and evidence of vessel remodeling (index, 1.6±0.3). Histopathological analysis showed pieces of fresh thrombus with inflammatory cell infiltrates (DES, 263±149 white blood cells per high-power field) and eosinophils (DES, 20±24 eosinophils per high-power field; sirolimus-eluting stents, 34±28; paclitaxel-eluting stents, 6±6; P for sirolimus-eluting stents versus paclitaxel-eluting stents=0.09). The mean number of eosinophils per high-power field was higher in specimens from very late DES ST (20±24) than in those from spontaneous acute myocardial infarction (7±10), early bare-metal stent ST (1±1), early DES ST (1±2), and late bare-metal stent ST (2±3; P from ANOVA=0.038). Eosinophil count correlated with ISA cross-sectional area, with an average increase of 5.4 eosinophils per high-power field per 1-mm2 increase in ISA cross-sectional area. Conclusions— Very late DES thrombosis is associated with histopathological signs of inflammation and intravascular ultrasound evidence of vessel remodeling. Compared with other causes of myocardial infarction, eosinophilic infiltrates are more common in thrombi harvested from very late DES thrombosis, particularly in sirolimus-eluting stents, and correlate with the extent of stent malapposition.

[1]  L. Thuesen,et al.  Late coronary stent thrombosis. , 2010, Minerva medica.

[2]  Simon Wandel,et al.  Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis , 2007, The Lancet.

[3]  M. Goldman,et al.  Hypereosinophilic syndromes , 2007, Orphanet journal of rare diseases.

[4]  W. Pichler,et al.  Delayed drug hypersensitivity reactions – new concepts , 2007, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[5]  Antonio Colombo,et al.  Offsetting Impact of Thrombosis and Restenosis on the Occurrence of Death and Myocardial Infarction After Paclitaxel-Eluting and Bare Metal Stent Implantation , 2007, Circulation.

[6]  F. Feres,et al.  Late incomplete apposition after drug-eluting stent implantation: incidence and potential for adverse clinical outcomes. , 2007, European heart journal.

[7]  StéphaneCook,et al.  Incomplete Stent Apposition and Very Late Stent Thrombosis After Drug-Eluting Stent Implantation , 2007 .

[8]  R. Virmani,et al.  Pathological Correlates of Late Drug-Eluting Stent Thrombosis: Strut Coverage as a Marker of Endothelialization , 2007, Circulation.

[9]  G. Mintz.  What to do about late incomplete stent apposition? , 2007, Circulation.

[10]  Rolf Vogel,et al.  Incomplete Stent Apposition and Very Late Stent Thrombosis After Drug-Eluting Stent Implantation , 2007, Circulation.

[11]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[12]  M. Hersberger,et al.  Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes. , 2007, European heart journal.

[13]  Ralph D'Agostino,et al.  Stent thrombosis in randomized clinical trials of drug-eluting stents. , 2007, The New England journal of medicine.

[14]  Marco Valgimigli,et al.  Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.

[15]  Neville Kukreja,et al.  Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study , 2007, The Lancet.

[16]  J. Mössner,et al.  Orphanet Journal of Rare Diseases BioMed Central Review Hereditary chronic pancreatitis , 2006 .

[17]  Anthony A Bavry,et al.  Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. , 2006, The American journal of medicine.

[18]  T. Donohue,et al.  Late thrombosis of drug-eluting stents after discontinuation of clopidogrel: report of two cases and review of the literature. , 2006, Connecticut medicine.

[19]  Michael Joner,et al.  Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. , 2006, Journal of the American College of Cardiology.

[20]  F. Feres,et al.  Very late thrombosis after drug‐eluting stents , 2006, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[21]  N. Weissman,et al.  Negative remodeling and calcified plaque in octogenarians with acute myocardial infarction: an intravascular ultrasound analysis. , 2006, Journal of the American College of Cardiology.

[22]  Matthew H Samore,et al.  Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. , 2006, Journal of the American College of Cardiology.

[23]  José R. Balaguer-Malfagón,et al.  [Stent thrombosis in the modern era: incidence, outcome and predictive factors]. , 2006, Revista espanola de cardiologia.

[24]  R. Korbut,et al.  The involvement of adhesion molecules and lipid mediators in the adhesion of human platelets to eosinophils. , 2005, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[25]  F. Eberli,et al.  Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. , 2005, The New England journal of medicine.

[26]  Patrick W Serruys,et al.  Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy , 2004, The Lancet.

[27]  Giuseppe Musumeci,et al.  Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting Stent: Should We Be Cautious? , 2004, Circulation.

[28]  W. Pichler,et al.  Delayed Drug Hypersensitivity Reactions , 2003, Annals of Internal Medicine.

[29]  D. Baim,et al.  Stent Thrombosis in the Modern Era: A Pooled Analysis of Multicenter Coronary Stent Clinical Trials , 2001, Circulation.

[30]  T. Nagasawa,et al.  Major basic protein binding to thrombomodulin potentially contributes to the thrombosis in patients with eosinophilia , 1995, British journal of haematology.